Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q2 FY2017 Earnings Presentation

70 slides from Daiichi Sankyo's earnings presentation, Oct 31, 2017

  1. Slide 1: Top Management Presentation: Financial Results of FY2017 Q2

    Top Management Presentation Financial Results of FY2017 Q2 (April 1 – September 30, 2017) DAIICHI SANKYO CO., LTD Sunao Manabe President and COO October 31, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Agenda

    Agenda  FY2017 Q2 Financial Results  FY2017 Revised Consolidated Forecast  Major Management Topics  Edoxaban (Lixiana)  US Pain Business  Japan Business  Shareholder Returns  R&D Update 3

  4. Slide 4: FY2017 Q2 Financial Results

    FY2017 Q2 Financial Results 4

  5. Slide 5: Overview of FY2017 Q2 Results

    Overview of FY2017 Q2 Results (Bn JPY) FY2016 Q2 YTD FY2017 Q2 YTD YoY Results Results +2.5% Revenue 458.0 469.4 +11.4 Cost of Sales 147.3 157.1 +9.8 SG&A Expenses 141.7 140.0 -1.7 R&D Expenses 95.8 123.6 +27.8 -33.5% Operating Profit 73.3 48.8 -24.5 Profit before Tax 71.9 51.2 -20.7 -30.0% Profit a

  6. Slide 6: Revenue

    Revenue Increased by 11.4 Bn JPY (Increased by 2.2 Bn JPY excl. forex impact) (Bn JPY) Japan FY2016 Results 458.0 Positive : Lixiana +8.2 Nexium +2.6 Pralia +2.6 Japan Daiichi Sankyo Espha (GE) +7.4 (incl. Vaccines, OTC) 23.1 (Telmisartan AG, Olmesartan AG, Rosuvastatin AG etc.) Daiichi Sankyo, Inc.

  7. Slide 7: Operating Profit

    Operating Profit Decreased by 24.5 Bn JPY (Decreased by 7.3 Bn JPY excl. forex impact and special items) (Bn JPY) FY2016 Results 73.3 Revenue +11.4 incl. forex impact +9.2 Revenue 73.3 11.4 Cost of Sales +13.2 Cost of Sales 13.2 Product mix due to impact of olmesartan LOE SG&A Expenses 70.6 0.9 Fore

  8. Slide 8: Special Items

    Special Items (Bn JPY) FY2016 Q2 YTD FY2017 Q2 YTD YoY Results Results Cost of Sales - Gain on sales of fixed assets -6.1 -6.1 SG&A Expenses Restructuring costs in EU +6.0 - -6.0 Impairment loss +30.2 R&D Expenses - +30.2 (incl. CL-108 +27.8) Total +6.0 +24.1 +18.1 - : Cost decrease items 8

  9. Slide 9: Profit Attributable to Owners of the Company

    Profit Attributable to Owners of the Company Decreased by 14.7 Bn JPY (Bn JPY) FY2016 Results 49.0 Operating Profit 24.5 Financial Income / Expenses -3.8 Financial Income Improvement of forex gains/ losses / Expenses 3.8 Income Taxes etc. 6.7 FY2016 Q2 YTD FY2017 Q2 YTD YoY Results Results Profit No

  10. Slide 10: Revenue: Major Business Units (incl. Forex Impact)

    Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2016 FY2017 vs. Forecast Q2 YTD Q2 YTD YoY (%) Results Results Japan 239.0 257.6 +18.6 48.1% Daiichi Sankyo Healthcare 32.2 35.8 +3.6 51.9% Daiichi Sankyo Inc. 70.3 42.0 -28.2 67.8% Olmesartan 36.7 10.3 -26.3 73.7% Welchol 19.5 19.7 +0.2

  11. Slide 11: Revenue: Major Products in Japan

    Revenue: Major Products in Japan (Bn JPY) FY2016 FY2017 vs. Forecast Q2 YTD Q2 YTD YoY (%) Results Results Nexium ulcer treatment 42.0 44.7 +2.6 48.6% Alzheimer’s disease Memary treatment 23.4 24.5 +1.1 45.4% Olmetec antihypertensive agent 34.9 31.9 -3.0 67.8% Lixiana anticoagulant 11.5 19.7 +8.2 50

  12. Slide 12: FY2017 Revised Consolidated Forecast

    FY2017 Revised Consolidated Forecast 12

  13. Slide 13: FY2017 Revised Consolidated Forecast

    FY2017 Revised Consolidated Forecast (JPY Bn) FY2017 FY2017 vs. Forecast Forecast Forecast (as of May.) Major factors (as of May.) (as of Oct.) - Gain on sales of fixed assets Revenue 930.0 930.0 0.0 -6.1 *booked in Q2 - Increase due to product mix Cost of Sales 340.0 337.0 -3.0 +3.0 SG&A Expenses 3

  14. Slide 14: Major Management Topics: Edoxaban (Lixiana)

    Major Management Topics • Edoxaban (Lixiana) • US Pain Business • Japan Business 14

  15. Slide 15: Direct Oral Anticoagulant (DOAC) Market

    Direct Oral Anticoagulant (DOAC) Market Global Currency Rate USD/JPY : 110 Copyright © 2017 QuintilesIMS Calculated based on MIDAS Sales Data *1: July 2012 – June 2013 15 Reprinted with permission *2: Percentage of DOAC prescription counts to total prescriptions of warfarin and DOAC

  16. Slide 16: DOAC Market in Japan and Germany

    DOAC Market in Japan and Germany Japan Germany *1 *2 Currency Rate USD/JPY : 110 Copyright © 2017 QuintilesIMS Calculated based on MIDAS Sales Data *1: July 2012 – June 2013 16 Reprinted with permission *2: Percentage of DOAC prescription counts to total prescriptions of warfarin and DOAC

  17. Slide 17: Lixiana: Growth in Japan

    Lixiana: Growth in Japan As of FY2017 Q2, Lixiana increased its sales share to 23.5%. (%) 50 40 30 Lixiana 23.5% Product A 20 Product B 10 Product C 0 Copyright © 2017 QuintilesIMS Calculated based on JPM FY2014 Q1 - FY2017 Q2 17 Reprinted with permission

  18. Slide 18: Lixiana: Growth in Japan

    Lixiana: Growth in Japan Lixiana has reached top Rxs share since Mar. 2017 in prescription number of new patients for AF+VTE. The share expanded to 38.6% in Sep. 2017. (%) 38.6% 40 35 30 25 20 15 10 5 0 Source :Medi-trend 18

  19. Slide 19: Lixiana: Growth in Germany and South Korea

    Lixiana: Growth in Germany and South Korea Steady uptake of sales share after launch (%) Germany (%) South Korea 10 9.2% 20 18.5% 18 8 16 14 6 12 10 4 8 6 2 4 2 0 0 Copyright © 2017 QuintilesIMS Calculated based on MIDAS Sales Data Reprinted with permission 19

  20. Slide 20: Major Management Topics: US Pain Business

    Major Management Topics • Edoxaban (LIXIANA) • US Pain Business • Japan Business 20

  21. Slide 21: Changes in US Pain Business

    Changes in US Pain Business  CL-108  Jan. 2017, received Complete Response Letter from FDA  Aug. 2017, decided to return all of rights regarding CL-108 to Charleston Laboratories, Inc.  Mirogabalin  In the phase 3 ALDAY clinical trials evaluating mirogabalin for the treatment of pain associated

  22. Slide 22: DSI: Commitments in Pain Care

    DSI: Commitments in Pain Care  Daiichi Sankyo recognizes that pain management may require the appropriate use of prescription medicines including controlled substances such as opioids, which may be subject to many safety concerns including diversion, misuse, abuse, addiction, or overdose.  We are

  23. Slide 23: Three Pain Management Products in US

    Three Pain Management Products in US  Expand sales of  Responsibly launch  Prepare for launch Movantik™ MorphaBond™ ER of RoxyBond™  Opioid-Induced  Single-agent, extended  First and only immediate- Constipation (OIC) release morphine approved release opioid approved by  Raised awareness of b

  24. Slide 24: Major Management Topics: Japan Business

    Major Management Topics • Edoxaban (Lixiana) • US Pain Business • Japan Business 24

  25. Slide 25: VIMPAT: Additional Indication and Lift of Prescription Period Restriction

    VIMPAT: Additional Indication and Lift of Prescription Period Restriction  Aug. 2017, approved as monotherapy* for partial- onset seizure in epilepsy patients * Conventionally approved and marketed as an adjunctive therapy  Sep. 2017, lifted restriction on prescription period  UCB Japan manufactu

  26. Slide 26: VIMPAT: New Options for Epilepsy Medication

    VIMPAT: New Options for Epilepsy Medication  Approval of VIMPAT for monotherapy expand the target patient population Adjunctive Monotherapy + therapy Age Number of epilepsy patients ca.1M1) Epilepsy treated Symptoms patients ca. 0.8M2) Adult and senior patients ca. 0.65M3) Partial-onset Seizures Ef

  27. Slide 27: CANALIA Combination Tablet: Launched in Sep. 2017

    CANALIA Combination Tablet: Launched in Sep. 2017  Combination product of Tenelia and Canaglu tablets, two agents for type 2 diabetes mellitus treatments, created by Mitsubishi Tanabe Pharma Corporation  DPP-4 inhibitor/SGLT2 inhibitor combination drug, first launched in Japan  Approximately 10%

  28. Slide 28: Expansion of Product Portfolio in Japan

    Expansion of Product Portfolio in Japan  Achieved the primary endpoint in Phase 3 studies  Mirogabalin (Japan, Asia)  Patients with post-herpetic neuralgia and patients with diabetic peripheral neuropathic pain  Evaluated weekly average daily pain score from baseline  Esaxerenone/CS-3150 (Japan

  29. Slide 29: Shareholder Returns

    Shareholder Returns 29

  30. Slide 30: Shareholder Returns

    Shareholder Returns Shareholder Returns Policy during 5YBP*  Total return ratio: 100% or more  Annual ordinary dividend: more than 70 JPY  Flexible acquisition of own shares * 5YBP: 5-year Business Plan (FY2016 - FY2020) FY2016 FY2017 (Target Results Plan during 5YBP) Total return ratio 180.7% 10

  31. Slide 31: R&D Update

    R&D Update Glenn Gormley MD PhD Senior Executive Officer Global Head of R&D 31

  32. Slide 32: Agenda

    Agenda  R&D Focus and Efficiency  Oncology Update  DS-8201 Update  U3-1402 Update  New Projects Entered to Clinical Phase  New Collaboration in Oncology  Esaxerenone/CS-3150 Update  FY2017 Major R&D Milestone Events  Announcement of R&D Day  Back-up  Pipeline Chart  Study Designs of Majo

  33. Slide 33: R&D Focus and Efficiency

    R&D Focus and Efficiency 33

  34. Slide 34: R&D Focus and Efficiency

    R&D Focus and Efficiency  Prioritize projects  Invest selectively to oncology, especially to ADC/AML Franchises  Accelerate clinical development by focused investment <Image> External resources CVM/  Projects which do not align with our CVM/ Others strategic focus may be out-licensed Others to p

  35. Slide 35: DS-8201 Update, U3-1402 Update

    ADC DS-8201 Update U3-1402 Update 35

  36. Slide 36: DS-8201: P1 Study Part 2d Result

    ESMO2017 ADC DS-8201: P1 Study Part 2d Result Poster  Results of HER2 expressing solid tumors (other than breast cancer and gastric cancer) in the phase 1 study were presented. (BC and GC results were presented at ASCO 2017) Efficacy data of part 2d was presented at ESMO (N=25) 36

  37. Slide 37: DS-8201: P1 Study Part 2d Patient Demographics

    ESMO2017 ADC DS-8201: P1 Study Part 2d Patient Demographics Poster Patient characteristic Part 2d (N=25) Age, median (range) 60.0 (44-72) Number of prior regimens, median (range) 3 (0-10) Tumor Type Part 2d (N=25) Colorectal 11 (44.0%) NSCLC 6 (24.0%) Salivary 4 (16.0%) Others† 4 (16.0%) † 2 Paget’s

  38. Slide 38: DS-8201: P1 Study Part 2d Efficacy (6.4mg/kg)

    ESMO2017 ADC DS-8201: P1 Study Part 2d Efficacy (6.4mg/kg) Poster ORR N (%) ‡ DCR N (%) Part 2d overall † 7/22 (31.8) 18/22 (81.8) Colorectal Cancer 2/10 (20.0) 8/10 (80.0) NSCLC 1/5 (20.0) 3/5 (60.0) Salivary Cancer 3/4 (75.0) 4/4 (100.0) Others § 1/3 (33.3) 3/3 (100.0) † 3 of 25 patients in 2d wer

  39. Slide 39: DS-8201: P1 Study Part 2d Efficacy

    ESMO2017 ADC DS-8201: P1 Study Part 2d Efficacy Poster Tumor size: Maximum % change from baseline Tumor shrinkage was observed in most patients 39

  40. Slide 40: DS-8201: P1 Study Part 2d CT Imaging

    ESMO2017 ADC DS-8201: P1 Study Part 2d CT Imaging Poster 59 y/o Male Colorectal cancer with Liver Mets, IHC 3+ (6.4mg/kg) After 8 cycles Liver metastasis Day 0 Day 175 More than 30% tumor shrinkage was observed (PR) 40

  41. Slide 41: DS-8201: Part 1 to Part 2 Safety Profile Dose

    ESMO2017 ADC DS-8201: Part 1 to Part 2 Safety Profile Poster Dose escalation (Part 1) Dose expansion (Part 2) HNSTD Part 2-a Breast cancer or Gastric/GEJ adenocarcinoma HER2 positive 8.0mg/kg T-DM1 pretreated BC mCRM with EXOC RP2D 3pts 6.4mg/kg Part 2-b Administered iv Q3W 6pts RP2D HER2 positive D

  42. Slide 42: DS-8201: P1 Study Safety – TEAE, any grade, >20%

    ESMO2017 ADC DS-8201: P1 Study Safety – TEAE, any grade, >20% Poster Preferred Term Grade 1 Grade 2 Grade 3 Grade 4 All (%) Part 1 +Part 2 Total (N=168) (%) (%) (%) (%) Hematologic Anemia 3.6 11.9 13.1 1.2 29.8 Platelet count decreased 11.9 7.7 6.5 3.0 29.2 Neutrophil count decreased 1.2 7.7 13.7 2.

  43. Slide 43: DS-8201: P1 Study Part 2d Conclusions

    ESMO2017 ADC DS-8201: P1 Study Part 2d Conclusions Poster  DS-8201 was well tolerated and MTD was not reached in the dose escalation part.  Of 22 evaluable patients treated in Part 2d, the ORR was 31.8% and DCR was 81.8%.  Most of the patients with HER2 expressing solid tumors had tumor shrinkage

  44. Slide 44: DS-8201: Development Plan

    ADC DS-8201: Development Plan Current Development Planned to start 2H FY2017 Planned 2016 2020 2024+ HER2+ breast cancer (T-DM1 failure) Phase 2 pivotal study ongoing BTD Tracking for 2020 submission HER2+ gastric cancer (Herceptin failure) Phase 2 pivotal study started (Japan, Korea) HER2+ breast a

  45. Slide 45: U3-1402: Development Plan

    ADC U3-1402: Development Plan  Clinical trial schedule FY2017 FY2018 FY2019 Phase 1/2 study ☆TLR HER3 positive refractory/metastatic breast cancer Phase 1 study EGFRm NSCLC  HER3 positive refractory/metastatic breast cancer Phase 1/2 study  Phase 1 study to be presented at conference in FY2018 

  46. Slide 46: New Projects Entered to Clinical Phase

    New Projects Entered to Clinical Phase 46

  47. Slide 47: DS-1205: AXL Inhibitor Summary

    DS-1205: AXL Inhibitor Summary  AXL up-regulation is associated with poor prognosis in several cancers  Up-regulation of AXL is one mechanism of EGFR-TKI resistance in EGFR- mutant non-small cell lung cancer  DS-1205 is an orally available, potent and selective small-molecule inhibitor of the AXL

  48. Slide 48: DS-1205: Results of Pharmacology Study

    ESMO2017 DS-1205: Results of Pharmacology Study Poster Antitumor activity demonstrated in animal pharmacology study DS-1205 in combination with osimertinib significantly delays resistance in osimertinib acquired-resistance xenograft model 48

  49. Slide 49: New Collaboration in Oncology

    New Collaboration in Oncology ADC - Glycotope: ADC Franchise AML - MD Anderson: AML Franchise 49

  50. Slide 50: Maximize ADC Technology: Collaboration with Glycotope

    ADC Maximize ADC Technology: Collaboration with Glycotope Partnerships to apply our ADC technology to new antibodies and targets Our proprietary linker and novel payload PankoMab-GEX® (Glycotope)  Strategic collaboration to develop an ADC by combining the TA- MUC1 antibody PankoMab-GEX® with our AD

  51. Slide 51: Collaboration with MD Anderson Cancer Center

    AML Collaboration with MD Anderson Cancer Center  MDACC  One of the largest integrated academic centers specializing in leukemia  Ideal partner to help advance Daiichi Sankyo’s growing AML portfolio  Purpose  Accelerate the development of novel therapies for AML  Conduct numerous non-clinical,

  52. Slide 52: Target DS Compounds and Image of Collaboration

    AML Target DS Compounds and Image of Collaboration  Target DS compounds  Quizartinib (FLT3-ITD inhibitor)  DS-3032 (MDM2 inhibitor)  DS-3201(EZH1/2 inhibitor)  PLX51107(BRD4 inhibitor) MDACC Daiichi Sankyo DS compound A Combo AB Pivotal DS compound B Combo AC Pivotal compound C Combo ABC (Not f

  53. Slide 53: Oncology Future Data Disclosure

    Oncology Future Data Disclosure ADC AML Dec. 2017 San Antonio Breast Cancer Symposium DS-8201: Breast cancer including HER2 low (Ph1) Dec. 2017 American Society of Hematology (ASH) DS-3201: Non-Hodgkin’s lymphoma (Ph1) 53

  54. Slide 54: Esaxerenone/CS-3150 Update

    Esaxerenone/CS-3150 Update 54

  55. Slide 55: Mineralocorticoid Receptor Related Hypertension and Diabetic Nephropathy

    Mineralocorticoid Receptor Related Hypertension and Diabetic Nephropathy Aldosterone dependent pathway Renin angiotensin system Angiotensin II Aldosterone-independent pathway AT1 receptor ARB(Olmesartan) Obesity DM High salt Aldosterone CS-3150 Mineralocorticoid Receptors (MR) Hypertension Diabetic

  56. Slide 56: Esaxerenone/CS-3150: P3 Study

    Esaxerenone/CS-3150: P3 Study  Hypertension  Phase 3 pivotal study (ESAX-HTN study)  Efficacy and safety compared to eplerenone in patients with essential hypertension was evaluated  Topline Result: achieved primary endpoint  NDA submission: FY2017 Q4  Diabetic nephropathy (DN)  Started phase

  57. Slide 57: FY2017 Major R&D Milestone Events (1)

    FY2017 Major R&D Milestone Events (1) FY18-Q1 Project Indication/Study Q1 Q2 Q3 Q4 ~ Tenosynovial giant cell tumor Pexidartinib TLR Submission Phase 3 study (US/EU) QuANTUM-R AML 2nd line treatment Interim Quizartinib Analysis TLR Phase 3 study (US/EU/Asia) HER2-positive Breast Cancer (T-DM1 resista

  58. Slide 58: FY2017 Major R&D Milestone Events (2)

    FY2017 Major R&D Milestone Events (2) FY18-Q1 Project Indication/Study Q1 Q2 Q3 Q4 ~ Fibromyalgia Phase 3 study (US/EU) TLR Mirogabalin PHN Phase 3 study (JP/Asia) TLR Submission DPNP Phase 3 study (JP/Asia) TLR Hypertension Phase 3 study (JP) TLR Submission Esaxerenone /CS-3150 Study Diabetic nephr

  59. Slide 59: DS R&D Day 2017

    DS R&D Day 2017  Date: December 13, 2017 (15:30 – 17:30)  Location: Daiichi Sankyo Headquarter Office  Presenters:  Dr. Glenn Gormley  Sr. Executive Officer, Global R&D Head  Dr. Antoine Yver  Global Head of Oncology R&D, Head of Cancer Enterprise 59

  60. Slide 60: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected] 60

  61. Slide 61: Appendix

    Appendix - Pipeline chart - Study designs of major clinical studies - Abbreviations 61

  62. Slide 62: Major R&D Pipeline

    Major R&D Pipeline As of October 2017 Therapeutic area Phase 1 Phase 2 Phase 3 Application  DS-3032 (US/JP)  DS-8273 (US)  Patritumab (EU)  Denosumab (JP) (MDM2 inhibitor) (Anti-DR5 antibody) (U3-1287 / Anti-HER3 antibody) (AMG 162 / Breast cancer adjuvant/ Anti-RANKL antibody)  PLX7486 (US) 

  63. Slide 63: DS-8201: HER2 Positive Breast Cancer Pivotal P2 Study

    DS-8201: HER2 Positive Breast Cancer Pivotal P2 Study (JP/US/EU) Part 1 5.4mg/kg HER2+ T-DM1 resistant/ refractory breast cancer Evaluate PK and 6.4mg/kg select 2 doses (N=60) 7.4mg/kg HER2+ T-DM1 resistant/ Recommended dose from above -1 Determine refractory breast cancer Recommended dose recommend

  64. Slide 64: DS-8201: HER2 Positive Gastric Cancer Pivotal P2 Study

    DS-8201: HER2 Positive Gastric Cancer Pivotal P2 Study (JP/Asia) Pivotal cohort DS-8201 HER2 positive gastric or Evaluate efficacy gastroesophageal junction and safety adenocarcinoma Irinotecan or paclitaxel* Exploratory cohort * Doctor’s choice treatment HER2 low expressing gastric or Evaluate effi

  65. Slide 65: DS-8201: P1b Nivolumab Combination Study (US/EU)

    DS-8201: P1b Nivolumab Combination Study (US/EU) Part 1: dose escalation HER2-expressing DS-8201 breast cancer refractory to standard + Determine recommended dose therapies / no available standard therapy Nivolumab Part 2: dose expansion HER2-expressing advanced/metastatic DS-8201 breast cancer Eval

  66. Slide 66: U3-1402: HER3 Positive Breast Cancer P1/2 Study (JP)

    U3-1402: HER3 Positive Breast Cancer P1/2 Study (JP) 1.6 mg/kg Phase 1: dose escalation 3.2 mg/kg Evaluate safety and HER3 positive refractory/ tolerability and confirm metastatic breast cancer 4.8 mg/kg maximum dose 6.4 mg/kg Phase 1: dose finding HER3 positive refractory/ Recommended dose Evaluate

  67. Slide 67: U3-1402: EGFRm NSCLC P1 Study (US)

    U3-1402: EGFRm NSCLC P1 Study (US) Part 1: dose escalation 3.2 mg/kg Metastatic or unresectable EGFR- 6.4 mg/kg Evaluate mutant non-small cell lung cancer who recommended dose has acquired resistance to EGFR TKI 9.6 mg/kg 12.8 mg/kg Part 2: dose expansion Metastatic or unresectable EGFR- Recommended

  68. Slide 68: DS-1205: FIH P1 Osimertinib Combination Study (US)

    DS-1205: FIH P1 Osimertinib Combination Study (US) Part 1: dose escalation DS-1205 200/400/600/800mg Evaluate safety and Metastatic or unresectable tolerability and confirm EGFR-mutant non-small cell + recommended dose for lung cancer Osimertinib 80mg part 2 Part 2: dose expansion DS-1205 recommende

  69. Slide 69: CS-3150: Diabetic Nephropathy P3 Study (ESAX-DN Study)

    CS-3150: Diabetic Nephropathy P3 Study (ESAX-DN Study) (JP) Esaxerenone 2.5mg/day Improvement effect of Type 2 DM patients (start from 1.25mg) urinary albumin-creatinine with microalbuminuria ratio (UACR)* Placebo ARB or ACE inhibitor Dosing period: 52 weeks Study patients Type 2 DM patients with mi

  70. Slide 70: Abbreviations

    Abbreviations Abbreviation BTD Breakthrough designation CR Complete response DCR Disease control rate DLT Dose limiting toxicity DOR Duration of response EGFR Epidermal growth factor receptor MTD Maximum tolerated dose NSCLC Non-small-cell lung cancer ORR Overall response rate Objective response rat

Daiichi Sankyo Company — Q2 FY2017 Earnings Presentation on 6ix